MtheraPharma Co., Ltd., 38, Magokjungang 8-ro 1-gil, Gangseo-gu, Seoul, the Republic of Korea.
MtheraPharma Co., Ltd., 38, Magokjungang 8-ro 1-gil, Gangseo-gu, Seoul, the Republic of Korea.
Biomed Pharmacother. 2022 Oct;154:113637. doi: 10.1016/j.biopha.2022.113637. Epub 2022 Sep 1.
Parkinson's disease (PD) is the second most common neurodegenerative disease, after Alzheimer's disease, and becomes increasingly prevalent with age. α-Synuclein (α-syn) forms the major filamentous component of Lewy bodies, which are pathological hallmarks of α-synucleinopathies such as PD. We evaluated the neuroprotective effects of MT101-5, a standardized herbal formula that consists of an ethanolic extract of Genkwae Flos, Clematidis Radix, and Gastrodiae Rhizoma, against α-synuclein-induced cytotoxicity in vivo. MT101-5 protected against behavioral deficits and loss of dopaminergic neurons in human α-syn-overexpressing transgenic mice after treatment with 30 mg/kg/day for 5 months. We investigated transcriptomic changes within MT101-5 mechanisms of action (MOA) suppressing α-syn aggregation in an α-synuclein preformed fibril (α-syn PFF) mouse model of sporadic PD. We found that inhibition of α-syn fibril formation was associated with changes in transcripts in mitochondrial biogenesis, electron transport, chaperones, and proteasomes following treatment with MT101-5. These results suggest that the mixed herbal formula MT101-5 may be used as a pharmaceutical agent for preventing or improving PD.
帕金森病（PD）是仅次于阿尔茨海默病的第二常见神经退行性疾病，随着年龄的增长而变得越来越普遍。α-突触核蛋白（α-syn）形成路易体的主要丝状成分，路易体是包括 PD 在内的α-突触核蛋白病的病理学标志物。我们评估了 MT101-5 的神经保护作用，MT101-5 是一种标准化的草药配方，由金银花、威灵仙和天麻的乙醇提取物组成，用于治疗体内α-突触核蛋白诱导的细胞毒性。MT101-5 在 30mg/kg/天治疗 5 个月后，可预防人类α-syn 过表达转基因小鼠的行为缺陷和多巴胺能神经元丢失。我们研究了 MT101-5 作用机制（MOA）在α-突触核蛋白预形成纤维（α-syn PFF）小鼠散发性 PD 模型中抑制α-syn 聚集的转录组变化。我们发现，抑制α-syn 纤维形成与 MT101-5 治疗后线粒体生物发生、电子传递、伴侣蛋白和蛋白酶体的转录本变化有关。这些结果表明，混合草药配方 MT101-5 可作为预防或改善 PD 的药物。
